Skip to content

Role of Vardhamana Nagabala Rasayana and Samvardhana ghrita in children with cerebral palsy.

Randomised open-label clinical study on the efficacy of vardhamana nagabala rasayana in comparison with samvardhana ghrita on neuromuscular activity in children with cerebral palsy. - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/103233
Enrollment
30
Registered
2026-02-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G809- Cerebral palsy, unspecified

Interventions

None listed

Sponsors

Dr Monika Singh Chauhan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Participants between the age group of 3 years to 7 years. 2. Participants diagnosed with cerebral palsy as per ICD 11 criteria 3. Participants diagnosed with spastic hemiplegia, diplegia, dyskinetic, ataxic cerebral palsy. 4. Participants whose parents or legal guardians are willing to sign the written informed consent form. 5. Participants who have been already diagnosed with cerebral palsy and are on supportive treatments like physiotherapy, ADL (activities of daily living) training will be included.

Exclusion criteria

Exclusion criteria: 1. Children of CP with major congenital anomalies 2. Children who are currently on medications like baclofen, diazepam, tizanidine. 3. Children with Cerebral palsy associated with other illness like respiratory complications, orthopedic complications, contractures, severe neuromuscular conditions. 4. Children diagnosed with spastic quadriplegia.

Design outcomes

Primary

MeasureTime frame
Significant improvement in neuromuscular activity in participants with cerebral palsy assessed with Coordination GMFM 66 (Gross Motor Function Measure) power-muscle power grading balance-paediatric balance scaleTimepoint: Group A- 0th, 19th, 27th, 35th day Group B- 0th, 30th, 45th, 60th day

Secondary

MeasureTime frame
Generation of in depth analyzed data on the different aspects of the disease. Generation of data on possible unexpected drug reaction.Timepoint: Group A- 0th, 19th, 27th, 35th day Group B- 0th, 30th, 45th, 60th day

Countries

India

Contacts

Public ContactDr Sudheer B R

Sri Sri College of Ayurvedic Science and Research, Bangalore.

sudheerbrao@yahoo.co.in9900175777

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026